The National Vaccine Commission asked the government to approve a Bt 5 million plan to develop and produce a vaccine against the seven deadly diseases: dengue hemorrhagic fever, diphtheria, pertussis, tetanus, Japanese encephalitis, hepatitis B and tuberculosis – which affect thousands of people every year.
At present, Thailand BT spends around 3 billion a year importing the vaccine.
If the Government approved the plan, Thailand spent 10 years in the development and production of a vaccine against dengue fever, two years for a cocktail of vaccines against diphtheria, pertussis and tetanus; four years for hepatitis type B, five years for Japanese encephalitis, and 10 years for a vaccine against tuberculosis.
The Government Pharmaceutical Organization conducted the trial on hepatitis B, Japanese encephalitis, and the cocktail for diphtheria, pertussis and tetanus.
Mahidol University conducted tests on a vaccine against dengue fever and the Queen of the Thai Red Cross Institute of Memorial Saovabha occurs tuberculosis vaccine on an industrial scale for export to Asia and Africa where the disease has widespread. Also be expanded BCG vaccine production plant.
Under the plan, Jurin will ask the government to establish a national institute for vaccine development, establishing a reserve of vaccines, and making them.
Dr. Sute Yoksa Center, Mahidol University for Vaccine Research, said his team of researchers has developed live attenuated vaccine against four strains of dengue hemorrhagic fever.
Since beginning his project in 2005, his current team could produce a prototype virus, dengue types 1-4 combines the most common mosquito-born disease in Thailand and South East Asia.
After testing the prototype of the dengue virus in animal testing – in long-tailed macaques – Sute said the prototype vaccine that is used to produce the live attenuated vaccine may increase immunity to a more promising.
He said his team had asked the government to allocate BT150 million to support construction of a pilot plant to conduct clinical trials and production of dengue hemorrhagic fever.
He said if this pilot plant meets World Health Organization’s certification, it could produce a vaccine for testing in humans and for export to other countries facing outbreaks of both diseases.
His team is waiting to test the vaccine in human trial in the next two years and expects to complete the trial within eight years.
The first phase of human trial tests involved 50 volunteers, and the second will run 400-500 volunteers, and the third phase will include more than 1,000 volunteers in South East Asia, South Asia, and Latin America .